AR119871A1 - Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátricos - Google Patents

Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátricos

Info

Publication number
AR119871A1
AR119871A1 ARP200102442A ARP200102442A AR119871A1 AR 119871 A1 AR119871 A1 AR 119871A1 AR P200102442 A ARP200102442 A AR P200102442A AR P200102442 A ARP200102442 A AR P200102442A AR 119871 A1 AR119871 A1 AR 119871A1
Authority
AR
Argentina
Prior art keywords
subject
methods
cln2
disease
cln2 disease
Prior art date
Application number
ARP200102442A
Other languages
English (en)
Inventor
David Jacoby
Joshua Henshaw
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR119871A1 publication Critical patent/AR119871A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)

Abstract

Se proporcionan aquí métodos para tratar la enfermedad de lipofuscinosis neuronal ceroidea (CLN2) en un sujeto menor de 3 años de edad. En modalidades ejemplares, el método comprende administrar al sujeto una formulación que comprende tripeptidil peptidasa-1 humana recombinante (rhTPP1) en una cantidad efectiva para tratar la enfermedad CLN2 en el sujeto. También se proporcionan métodos para retrasar la aparición de la enfermedad CLN2, o un síntoma de la misma, en un sujeto menor de 3 años. En modalidades ejemplares, el método comprende administrar al sujeto una formulación que comprende tripeptidil peptidasa-1 humana recombinante (rhTPP1) en una cantidad efectiva para retrasar la aparición de la enfermedad o síntoma de CLN2 en el sujeto.
ARP200102442A 2019-08-29 2020-08-31 Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátricos AR119871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962893535P 2019-08-29 2019-08-29

Publications (1)

Publication Number Publication Date
AR119871A1 true AR119871A1 (es) 2022-01-19

Family

ID=72470612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102442A AR119871A1 (es) 2019-08-29 2020-08-31 Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátricos

Country Status (15)

Country Link
US (1) US20220273775A1 (es)
EP (1) EP4021575A1 (es)
JP (1) JP2022546042A (es)
KR (1) KR20220054375A (es)
CN (1) CN114828960A (es)
AR (1) AR119871A1 (es)
AU (1) AU2020336984A1 (es)
BR (1) BR112022003598A2 (es)
CA (1) CA3152521A1 (es)
CL (1) CL2022000496A1 (es)
HR (1) HRP20220370A1 (es)
IL (1) IL290763A (es)
MX (1) MX2022002451A (es)
TW (1) TW202122106A (es)
WO (1) WO2021042020A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) * 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
WO2017070678A1 (en) * 2015-10-23 2017-04-27 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit

Also Published As

Publication number Publication date
US20220273775A1 (en) 2022-09-01
AU2020336984A1 (en) 2022-03-10
HRP20220370A1 (hr) 2022-09-16
WO2021042020A1 (en) 2021-03-04
TW202122106A (zh) 2021-06-16
KR20220054375A (ko) 2022-05-02
MX2022002451A (es) 2022-06-02
EP4021575A1 (en) 2022-07-06
IL290763A (en) 2022-04-01
CN114828960A (zh) 2022-07-29
JP2022546042A (ja) 2022-11-02
CL2022000496A1 (es) 2022-10-21
CA3152521A1 (en) 2021-03-04
BR112022003598A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
WO2020047462A3 (en) Methods of treating aging-related disorders
Whittaker Laser acupuncture: past, present, and future
Cidral-Filho et al. Light-emitting diode therapy induces analgesia in a mouse model of postoperative pain through activation of peripheral opioid receptors and the L-arginine/nitric oxide pathway
EP4327873A3 (en) Tpp1 formulations and methods for treating cln2 disease
Blanchard et al. Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL)
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
Leonardi et al. A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis
Oh et al. Depressed facial scars successfully treated with autologous platelet-rich plasma and light-emitting diode phototherapy at 830 nm
Artzi et al. Fractional ablative CO2 laser followed by topical application of sodium stibogluconate for treatment of active cutaneous leishmaniasis: a randomized controlled trial
AR119871A1 (es) Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátricos
Kawecki et al. Computerized planimetry evaluation of hyperbaric oxygen therapy in the treatment of diabetic foot
Mohamady et al. Effect of selected exercise program on natural killer cytotoxic cells activity of post-mastectomy patients
WO2020061067A8 (en) Compositions and methods for treating bone injury
RU2743166C2 (ru) Косметический способ
RU2566201C1 (ru) Способ лечения витилиго
Mezghani et al. Low-level laser therapy: effects on human face aged skin and Cell viability of hela cells exposed to UV radiation
Ţiţ et al. The evaluation of the effectiveness of phytoestrogens in improving, reduction or suppression of the climacteric symptomatology
EA200801278A1 (ru) Способ коррекции функциональных расстройств организма человека
RU2488414C1 (ru) Способ лечения профессионального миофиброза верхних конечностей
Johar et al. Management of oral submucous fibrosis: A Review
Kumar et al. Management of diabetic foot ulcer by Nishadi yoga avachoornana-a case study
Hartmann et al. Treatment of vitiligo using targeted UVB-Intense Pulsed Light (IPL)-phototherapy: Evaluation of variables affecting therapeutic success
Sabade et al. THE CLINICAL STUDY OF THE EFFICACY OF VIDDHAGNI KARMA IN THE PAIN MANAGEMENT OF CALCANEAL SPUR
HOSSAIN et al. A pilot study on jimutaka vamana yoga in the management of eka kushta wsr to psoriasis.
Panchal et al. A Single Case Study of Cupping Therapy in AVABAHUK (Frozen Shoulder).